Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Contributed by: ACCESS Newswire

Logo

Tags

Clairvoyant Therapeutics

Healthcare & Pharmaceutical

Company Update

More Like This

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

PR Newswire associated0

B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin in Alcohol Use Disorder Trial at NYU and Silver Hill Hospital

CYB003 (12mg dose) demonstrated a rapid and statistically significant reduction in symptoms of depression at three weeks after a single dose, meeting the primary efficacy endpoint (Graphic: Business Wire)

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Trial of new psychedelic drug seeks patients with Treatment Resistant Depression

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

PR Newswire associated0

B.More Collaborator, Dr. Michael Bogenschutz, Awarded $15 Million NIDA Grant for Landmark Psilocybin Study in Opioid Use Disorder

Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

National call for volunteers to test ground-breaking psychedelic treatments for mental health conditions